Patents by Inventor Fergus Shanahan

Fergus Shanahan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF DETERMINING EFFICACY OF TREATMENTS OF DISEASES OF THE BOWEL
    Publication number: 20130217600
    Abstract: Novel methods of determining efficacy of a treatment of inflammatory diseases of the bowel in mammals are provided. The methods are of use in screening and determining the efficacy of treatments of inflammatory diseases of the bowel, and for determining the efficacy response of individual sufferers of inflammatory diseases of the bowel to a given regime. Kits for carrying out the method are also provided.
    Type: Application
    Filed: June 15, 2012
    Publication date: August 22, 2013
    Inventors: Ker-Sang Chen, John Kevin Collins, Barry Pius Kiely, Fangyi Luo, Liam Diarmuid O'Mahony, Ross Peter Phillipson, Fergus Shanahan
  • Methods of determining efficacy of treatments of diseases of the bowel
    Patent number: 8216563
    Abstract: Novel methods of determining efficacy of a treatment of inflammatory diseases of the bowel in mammals are provided. The methods are of use in screening and determining the efficacy of treatments of inflammatory diseases of the bowel, and for determining the efficacy response of individual sufferers of inflammatory diseases of the bowel to a given regime. Kits for carrying out the method are also provided.
    Type: Grant
    Filed: February 28, 2011
    Date of Patent: July 10, 2012
    Assignee: The Procter & Gamble Company
    Inventors: Ker-Sang Chen, John Kevin Collins, Barry Pius Kiely, Fangyi Luo, Liam Diarmuid O'Mahony, Ross Peter Phillipson, Fergus Shanahan
  • METHODS OF DETERMINING EFFICACY OF TREATMENTS OF DISEASES OF THE BOWEL
    Publication number: 20110152117
    Abstract: Novel methods of determining efficacy of a treatment of inflammatory diseases of the bowel in mammals are provided. The methods are of use in screening and determining the efficacy of treatments of inflammatory diseases of the bowel, and for determining the efficacy response of individual sufferers of inflammatory diseases of the bowel to a given regime. Kits for carrying out the method are also provided.
    Type: Application
    Filed: February 28, 2011
    Publication date: June 23, 2011
    Inventors: Ker-Sang Chen, John Kevin Collins, Barry Pius Kiely, Fangyi Luo, Liam Diarmuid O'Mahony, Ross Peter Phillipson, Fergus Shanahan
  • Methods of determining efficacy of treatments of inflammatory diseases of the bowel
    Patent number: 7923000
    Abstract: Novel methods of determining efficacy of a treatment of inflammatory diseases of the bowel in mammals are provided. The methods are of use in screening and determining the efficacy of treatments of inflammatory diseases of the bowel, and for determining the efficacy response of individual sufferers of inflammatory diseases of the bowel to a given regime. Kits for carrying out the method are also provided.
    Type: Grant
    Filed: March 26, 2004
    Date of Patent: April 12, 2011
    Assignee: The Procter & Gamble Company
    Inventors: Ker-Sang Chen, John Kevin Collins, Barry Pius Kiely, Fangyi Luo, Liam Diarmuid O'Mahony, Ross Peter Phillipson, Fergus Shanahan
  • Modulation of Tissue Fatty Acid Composition of a Host by Human Gut Bacteria
    Publication number: 20100284979
    Abstract: The current invention provides use of a CLA-producing bacterium for the in vivo conversion in the gut of polyunsaturated fatty acids to CLA. The CLA-producing bacterium is selected from one or more of the group consisting of propionibacteria, lactobacilli, lactococci and streptococci, and bifidobacteria.
    Type: Application
    Filed: September 30, 2008
    Publication date: November 11, 2010
    Applicants: UNIVERSITY COLLEGE CORK, NATIONAL UNIVERSITY OF IRELAND, CORK, TEAGASC, The Agriculture and Food Development Authority, ALIMENTARY HEALTH LTD.
    Inventors: Liam O'Mahony, Fergus Shanahan, Eamonn Quigley, Paul Ross, Catherine Stanton
  • BIFIDOBACTERIUM IN THE TREATMENT OF INFLAMMATORY DISEASE
    Publication number: 20100112003
    Abstract: A strain of Bifidobacterium isolated from resected and washed human gastrointestinal tract is significantly immunomodulatory following oral consumption in humans. The strain is useful in the prophylaxis and/or treatment of undesirable inflammatory activity, especially gastrointestinal inflammatory activity such as inflammatory bowel disease or irritable bowel syndrome. The inflammatory activity may also be due to cancer.
    Type: Application
    Filed: June 5, 2009
    Publication date: May 6, 2010
    Inventors: John Kevin Collins, Gerald Christopher O'Sullivan, Liam O'Mahony, Fergus Shanahan
  • BIFIDOBACTERIUM IN THE TREATMENT OF INFLAMMATORY DISEASE
    Publication number: 20080311080
    Abstract: A strain of Bifidobacterium isolated from resected and washed human gastrointestinal tract is significantly immunomodulatory following oral consumption in humans. The strain is useful in the prophylaxis and/or treatment of undesirable inflammatory activity, especially gastrointestinal inflammatory activity such as inflammatory bowel disease or irritable bowel syndrome. The inflammatory activity may also be due to cancer.
    Type: Application
    Filed: May 19, 2008
    Publication date: December 18, 2008
    Applicants: University College Cork - National University of Ireland, Cork
    Inventors: John Kevin Collins, Gerald Christopher O'Sullivan, Liam O'Mahony, Fergus Shanahan
  • Probiotic strains
    Patent number: 7390519
    Abstract: A Lactobacillus salivarius strain, AH102, AH103, AH105, AH109 or AH110 or mutants or variants thereof are useful in the prophylaxis and/or treatment of inflammatory activity especially undesirable gastrointestinal inflammatory activity, such as inflammatory bowel disease or irritable bowel syndrome.
    Type: Grant
    Filed: April 14, 2005
    Date of Patent: June 24, 2008
    Assignee: Alimentary Health Limited
    Inventors: John Kevin Collins, Gerald Christopher O'Sullivan, Liam O'Mahony, Fergus Shanahan, Barry Kiely
  • Bifidobacterium in the treatment of inflammatory disease
    Publication number: 20080057109
    Abstract: A strain of Bifidobacterium isolated from resected and washed human gastrointestinal tract is significantly immunomodulatory following oral consumption in humans. The strain is useful in the prophylaxis and/or treatment of undesirable inflammatory activity, especially gastrointestinal inflammatory activity such as inflammatory bowel disease or irritable bowel syndrome. The inflammatory activity may also be due to cancer.
    Type: Application
    Filed: January 29, 2007
    Publication date: March 6, 2008
    Inventors: John Collins, Gerald O'Sullivan, Liam O'Mahony, Fergus Shanahan
  • Bifidobacterium in the treatment of inflammatory disease
    Publication number: 20070141039
    Abstract: A strain of Bifidobacterium isolated from resected and washed human gastrointestinal tract is significantly immunomodulatory following oral consumption in humans. The strain is useful in the prophylaxis and/or treatment of undesirable inflammatory activity, especially gastrointestinal inflammatory activity such as inflammatory bowel disease or irritable bowel syndrome. The inflammatory activity may also be due to cancer.
    Type: Application
    Filed: June 29, 2006
    Publication date: June 21, 2007
    Applicants: University College Cork - National University of Ireland, Cork
    Inventors: John Collins, Gerald O'Sullivan, Liam O'Mahony, Fergus Shanahan
  • Bifidobacterium in the treatment of inflammatory disease
    Patent number: 7195906
    Abstract: A strain of Bifidobacterium isolated from resected and washed human gastrointestinal tract is significantly immunomodulatory following oral consumption in humans. The strain is useful in the prophylaxis and/or treatment of undesirable inflammatroy activity, especially gastrointestinal inflammatory activity such as inflammatory bowel disease or irritable bowel syndrome. The inflammatory activity may also be due to cancer.
    Type: Grant
    Filed: February 23, 2004
    Date of Patent: March 27, 2007
    Assignees: Enterprise Ireland (Trading as BioResearch Ireland), University College Cork--National University of Ireland
    Inventors: John Kevin Collins, Gerald Christopher O'Sullivan, Liam O'Mahony, Fergus Shanahan
  • Use of lactobacillus salivarius
    Publication number: 20060292133
    Abstract: Lactobacillus salivarius is useful in the prophylaxis or treatment of undesirable inflammatory activity, especially gastrointestinal inflammatory activity such as inflammatory bowel disease or irritable bowel syndrome. The inflammatory activity may also be due to cancer. The Lactobacillus salivarius is of human origin isolated from resected and washed human gastrointestinal tract. One such strain is UCC 118 described in WO-A-9835014.
    Type: Application
    Filed: December 20, 2005
    Publication date: December 28, 2006
    Inventors: John Collins, Gerald O'Sullivan, Liam O'Mahony, Fergus Shanahan
  • Probiotics in the treatment of atypical depression and other disorders characterised by hypothalamic pitiuitary-ardrenal axis over activity
    Publication number: 20060204485
    Abstract: A method of treating a disorder characterized by hypothalamic-pituitary-adrenal axis over-activity comprising administering to a subject a probiotic bacterium.
    Type: Application
    Filed: May 15, 2006
    Publication date: September 14, 2006
    Inventors: Timothy Dinan, Liam O'Mahony, Barry Kiely, Eamonn Quigley, Fergus Shanahan, John Collins
  • Probiotic bifidobacterium strains
    Publication number: 20060121015
    Abstract: A Bifidobacterium strain, AH208, AH209, AH210, AH211, AH212 or AH214 or mutants or variants thereof are useful in the prophylaxis and/or treatment of inflammatory activity especially undesirable gastrointestinal inflammatory activity, such as inflammatory bowel disease or irritable bowel syndrome.
    Type: Application
    Filed: June 10, 2005
    Publication date: June 8, 2006
    Inventors: John Collins, Gerald O'Sullivan, Liam O'Mahony, Fergus Shanahan, Barry Kiely
  • Formulation comprising a bacterial strain
    Publication number: 20060088514
    Abstract: An injectable formulation of a bacterial strain such as a Lactobacillus salivarius strain is useful in treating of inflammatory disorders such as colitis or arthritis.
    Type: Application
    Filed: September 29, 2005
    Publication date: April 27, 2006
    Inventors: Liam O'Mahony, Fergus Shanahan, Barry Kiely, John Collins, Gerald O'Sullivan
  • Probiotic lactobacillus salivarius strains
    Publication number: 20060078547
    Abstract: A Lactobacillus salivarius strain, AH102, AH103, AH105, AH109 or AH110 or mutants or variants thereof are useful in the prophylaxis and/or treatment of inflammatory activity especially undesirable gastrointestinal inflammatory activity, such as inflammatory bowel disease or irritable bowel syndrome.
    Type: Application
    Filed: April 14, 2005
    Publication date: April 13, 2006
    Inventors: John Collins, Gerald O'Sullivan, Liam O'Mahony, Fergus Shanahan, Barry Kiely
  • Bifidobacterium in the treatment of inflammatory disease
    Publication number: 20060002908
    Abstract: A strain of Bifidobacterium isolated from resected and washed human gastrointestinal tract is significantly immunomodulatory following oral consumption in humans. The strain is useful in the prophylaxis and/or treatment of undesirable inflammatroy activity, especially gastrointestinal inflammatory activity such as inflammatory bowel disease or irritable bowel syndrome. The inflammatory activity may also be due to cancer.
    Type: Application
    Filed: October 29, 2004
    Publication date: January 5, 2006
    Applicants: National University
    Inventors: John Collins, Gerald O'Sullivan, Liam O'Mahony, Fergus Shanahan
  • Bifidobacterium in the treatment of inflammatory disease
    Publication number: 20050214272
    Abstract: A strain of Bifidobacterium isolated from resected and washed human gastrointestinal tract is significantly immunomodulatory following oral consumption in humans. The strain is useful in the prophylaxis and/or treatment of undesirable inflammatroy activity, especially gastrointestinal inflammatory activity such as inflammatory bowel disease or irritable bowel syndrome. The inflammatory activity may also be due to cancer.
    Type: Application
    Filed: October 4, 2004
    Publication date: September 29, 2005
    Inventors: John Collins, Gerald O'Sullivan, Liam O'Mahony, Fergus Shanahan
  • Use of lactobacillus salivarius
    Publication number: 20050084482
    Abstract: Lactobacillus salivarius is useful in the prophylaxis or treatment of undesirable inflammatory activity, especially gastrointestinal inflammatory activity such as inflammatory bowel disease or irritable bowel syndrome. The inflammatory activity may also be due to cancer. The Lactobacillus salivarius is of human origin isolated from resected and washed human gastrointestinal tract. One such strain is UCC 118 described in WO-A-9835014.
    Type: Application
    Filed: March 19, 2004
    Publication date: April 21, 2005
    Inventors: John Collins, Gerald O'Sullivan, Liam O'Mahony, Fergus Shanahan
  • Bifidobacterium in the treatment of inflammatory disease
    Publication number: 20050074441
    Abstract: A strain of Bifidobacterium isolated from resected and washed human gastrointestinal tract is significantly immunomodulatory following oral consumption in humans. The strain is useful in the prophylaxis and/or treatment of undesirable inflammatroy activity, especially gastrointestinal inflammatory activity such as inflammatory bowel disease or irritable bowel syndrome. The inflammatory activity may also be due to cancer.
    Type: Application
    Filed: February 23, 2004
    Publication date: April 7, 2005
    Inventors: John Collins, Gerald O'Sullivan, Liam O'Mahony, Fergus Shanahan